Related Experiment Video

Updated: Oct 27, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.0K

TrkB/BDNF Signaling Could Be a New Therapeutic Target for Pancreatic Cancer

Yasuhiro Oyama1, Shinjiro Nagao1, Lin Na1

  • 1Departments of Cancer Therapy and Research, Kyushu University, Fukuoka, Japan.

Anticancer Research
|July 20, 2021
PubMed
Abstract

Insights

Targeting Tropomyosin-related kinase B (TrkB)/brain-derived neurotrophic factor (BDNF) signaling significantly reduced pancreatic ductal adenocarcinoma (PDAC) cell proliferation and invasiveness. This suggests TrkB/BDNF signaling is a promising therapeutic target for refractory PDAC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Tropomyosin-related kinase B (TrkB)/brain-derived neurotrophic factor (BDNF) signaling is implicated in the malignant progression of aggressive cancers.
  • Understanding TrkB/BDNF signaling in pancreatic ductal adenocarcinoma (PDAC) is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the biological significance of TrkB/BDNF signaling in PDAC cells.
  • To evaluate TrkB/BDNF signaling as a potential therapeutic target for refractory solid cancers.

Main Methods:

  • Utilized three PDAC cell lines to assess proliferation and invasiveness.
  • Employed small interfering RNA (siRNA) and the TrkB inhibitor k252a to block TrkB/BDNF signaling.

Main Results:

  • All tested PDAC cell lines expressed both TrkB and BDNF.
  • Inhibition of TrkB/BDNF signaling significantly decreased invasiveness in PANC-1 and SUIT-2 cells.
  • TrkB inhibition via siRNA or k252a significantly reduced proliferation in PDAC cells.

Conclusions:

  • TrkB/BDNF signaling represents a potential novel therapeutic target for PDAC.
  • Targeting TrkB/BDNF signaling may offer a conclusive treatment strategy for refractory solid cancers.
Keywords:
BDNFTrkBinvasionpancreatic cancerproliferation

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.2K
Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma06:21

Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma

Published on: November 19, 2019

11.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
81.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.3K